Anavo Therapeutics GmbH

https://www.anavotx.com

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, MRL Ventures Fund, and Bioqube Ventures. *

	Start	2021-08-16 announced
	Group	Anavo Therapeutics (Group)
	Industry	cancer drug
	Industry 2	allosteric phosphatase modulator
	Person	Zech, Birgit (Anavo Therapeutics 202104 CEO before Gotham Therapeutics + X-Rx + MAB Discovery + Pieris + Axxima)
	Person 2	Müller, Gerhard (Gotham Therapeutics 201708– CSO before Mercachem BV + Proteros Fragments + Axxima + Organon + Bayer)

	Region	Heidelberg
	Country	Germany
	Street	582 Im Neuenheimer Feld c/o BioRN Network e. V.
	City	69120 Heidelberg
		Address record changed: 2023-05-06

Basic data	Employees	n. a.

		* Document for »About Section«: Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg.

		Record changed: 2023-12-30